Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of 2,6-Diaminopurine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.79 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.79 |
| ▸ | DPP4 | P27487 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 7/20 | 0.54 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.50 |
| ▸ | MGMT | P16455 | 5/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 6/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.46 |
| ▸ | PI4KA | P42356 | 2/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2,6-Diaminopurine SCHEMBL4535059 | 1.00 | PDPK1 (0.79) | PDPK1GDADPP4CDK2MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL30680639 | 1.00 | PDPK1 (0.79) | PDPK1GDADPP4CDK2MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL8079030 | 0.98 | PDPK1 (0.77) | PDPK1GDADPP4CDK2MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL9424492 | 0.95 | PDPK1 (0.72) | PDPK1GDADPP4CDK2MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL24053 | 0.89 | PDPK1 (1.00) | PDPK1GDADPP4CDK2MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL8757979 | 0.87 | PDPK1 (0.96) | PDPK1GDADPP4CDK2MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL28206545 | 0.87 | PDPK1 (0.96) | PDPK1GDADPP4CDK2MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL27891733 | 0.87 | PDPK1 (0.96) | PDPK1GDADPP4CDK2MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL13857840 | 0.86 | PDPK1 (0.79) | PDPK1GDADPP4CDK2MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL29143272 | 0.85 | PDPK1 (0.92) | PDPK1GDADPP4CDK2MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286235-A1 | METHODS FOR INCREASING IN VIVO EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS | TOPIGEN PHARMACEUTIQUE INC. (CA) | 2010-11-11 | — | — | US | disclosed |
| US-7745420-B2 | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals | TOPIGEN PHARMACEUTIQUE, INC. (CA) | 2010-06-29 | — | — | US | disclosed |
| EP-1406667-B1 | METHODS FOR INCREASING IN VIVO EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS | TOPIGEN PHARMACEUTICALS INC (CA) | 2008-02-20 | — | — | EP | disclosed |
| US-20050032723-A1 | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals | PHARMAXIS LTD (AU) | 2005-02-10 | — | — | US | disclosed |
| EP-1406667-A2 | METHODS FOR INCREASING i IN VIVO /i EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS | Topigen Pharmaceutiques Inc (CA) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003004511-A2 | METHODS FOR INCREASING IN VIVO EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS | TOPIGEN PHARMACEUTIQUE INC.. (CA) | 2003-01-16 | — | — | WO | disclosed |